A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

Who May Qualify: - Are seen in the UT Houston Scleroderma Center (UTHSC) - Meet 2013 American college of rheumatology (ACR)/European league against rheumatism (EULAR) criteria or CREST criteria for SSc - Meet Rome IV criteria for constipation and/or significant bloating - Subject willing to sign an willing to sign a consent form form - Subject deemed likely to survive for ≥ 1 year after enrollment - Able to follow study procedure and follow-up - Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the treatment and follow-up period - Female subjects of childbearing potential must have a negative pregnancy test in the 72 hours before the procedure - Subjects who agree to adhere to a stable diet for at least 4 weeks before joining the study and throughout the study - Subjects must have an attending physician who will provide non-transplant care for the subject Who Should NOT Join This Trial: - Subjects with constipation and/or significant bloating from causes not attributed to SSc as determined by the treating physician (e.g., inflammatory bowel disease, medication, significant diabetes, or hypothyroidism, etc.) - Subjects unwilling to stop taking probiotic supplements during the duration of the study - Subjects that have post-total or hemicolectomy or the presence of a colostomy - Subjects unable to tolerate microbiome transplant via enema for any reason or swallow capsules - Subjects requiring systemic antibiotic therapy 4 weeks before the study - If subjects are on immunosuppression, the immunosuppression dose should be stable for at least 4 weeks before study enrollment Always talk to your doctor about whether this trial is right for you.